P661: Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studiesECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Dotan, I.(2,3);Ferrante, M.(4);Danese, S.(5,6);Bossuyt, P.(7);Kligys, K.(8);Neimark, E.(8);Zambrano, J.(8);Liao, X.(8);D'Haens, G.(9);
(1)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(4)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(6)Vita-Salute San Raffaele University, Gastroenterology, Milan, Italy;(7)Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;
P662: Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Lin, S.(1,2)*;Chanchlani, N.(1,2);Smith, R.(1,2);Roberts, C.(1,2);Nice, R.(3);McDonald, T.J.(3);Hamilton, B.(2);Bewshea, C.(2);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Ahmad, T.(1,2);
(1)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)Royal Devon University Healthcare NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;PANTS consortium
P663: Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC CohortECCO’23 CopenhagenYear: 2023
Authors: An, Y.K.(1)*;Lindsay, N.(2);Allan, N.(2);Khoo, E.(1);Fernandes, R.(1);Amiss, A.(2);Pham, H.(2);Wong, K.F.(2);Ooi, S.Y.(3);Thin, L.(4);Lightowler, D.(4);Connor, S.J.(5);Williams, A.J.(5);De Cruz, P.(6);Li Wai Suen, C.(6);Kariyawasam, V.(7);Mitrev, N.(7);Ghaly, S.(8);Andrews, J.M.(9);Christensen, B.(10);Sparrow, M.P.(11);White, L.S.(12);Bryant, R.V.(13);Ding, N.(14);Leong, R.(15);Van Langenberg, D.(16);Seltenreich, H.(17);Subramaniam, K.(18);Radford-Smith, G.(3);Begun, J.(19);
(1)Mater Hospital Brisbane, Department of Gastroenterology, Brisbane, Australia;(2)Mater Research Institute, IBD Research Group, Brisbane, Australia;(3)Royal Brisbane and Women's Hospital, Department of Gastroenterology, Brisbane, Australia;(4)Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia;(5)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(6)Austin Hospital, Department of Gastroenterology, Melbourne, Australia;(7)Blacktown Hospital, Department of Gastroenterology, Sydney, Australia;(8)St Vincent's Hospital Sydney, Department of Gastroenterology, Sydney, Australia;(9)Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia;(10)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(11)Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(12)Sunshine Coast University Hospital, Department of Gastroenterology, Brisbane, Australia;(13)The Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia;(14)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(15)Concord Hospital, Department of Gastroenterology, Sydney, Australia;(16)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(17)Costal Digestive Health, Clinical Research Unit, Brisbane, Australia;(18)Canberra Hospital, Department of Gastroenterology, Canberra, Australia;(19)Mater Hospital Brisbane, Department of Gastroenterolgy, Brisbane, Australia;Australia New Zealand IBD Consortium (ANZIBDC)
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBDECCO’23 CopenhagenYear: 2023
Authors: Vieujean, S.(1)*;Lindsay, J.O.(2,3);Rubin, D.(4);D'Amico, F.(5,6);Ahuja, V.(7);Silverberg, M.S.(8);Sood, A.(9);Yamamoto-Furusho, J.K.(10);Nagahori, M.(11);Watanabe, M.(12);Koutroubakis, I.E.(13);Foteinogiannopoulou, K.(13);Walsh, A.(14);Outtier, A.(15);Abreu, M.T.(16);Dubinsky, M.(17);Siegel, C.(18);Louis, E.(1);Dotan, I.(19);Reinisch, W.(20);Danese, S.(5);Peyrin-Biroulet, L.(21);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom;(3)The Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(4)University of Chicago, Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(5)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(6)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(7)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(8)Toronto Immune and Digestive Health Institute, Toronto Immune and Digestive Health Institute, Toronto, Canada;(9)Dayanand Medical College and Hospital, Department of Gastroenterology, Ludhiāna- Punjab, India;(10)Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Inflammatory Bowel Disease Clinic- Department of Gastroenterology, Tlalpa, Mexico;(11)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(12)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(13)University Hospital of Heraklion, Department of Gastroenterology, Heraklion- Crete, Greece;(14)Oxford University Hospitals NHS Foundation Trust and NIHR Biomedical Research Centre, Translational Gastroenterology Unit- John Radcliffe Hospital, Oxford, United Kingdom;(15)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)University of Miami Miller School of Medicine, Division of Gastroenterology- Department of Medicine, Miami- FL, United States;(17)Icahn School of Medicine, Division of Pediatric Gastroenterology and Nutrition, Mount Sinai- New York, United States;(18)Dartmouth-Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology and Hepatology, Lebanon, United States;(19)Rabin Medical Center- Sackler Faculty of Medicine, Division of Gastroenterology, Tel Aviv, Israel;(20)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(21)Nancy University Hospital- University of Lorraine, Department of Gastroenterology NGERE INSERM U1256, Vandœuvre-lès-Nancy, France;
P665: Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Auriat, O.(1);Lucats, L.(1)*;Badalamenti, S.(2);Kruger, A.(2);Wiekowski, M.(2);Glotfelty, L.(2);Van Hoogstraten, H.(3);Coulouvrat, C.(4);
(1)Sanofi Recherche & Développement - 1 avenue Pierre Brossolette, Sanofi Recherche & Développement - 1 avenue Pierre Brossolette, Chilly-Mazarin, France;(2)Sanofi Research and Development- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Sanofi Research and Development- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Bridgewater, United States;(3)Sanofi Global Medical Affairs- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Sanofi Global Medical Affairs- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Bridgewater, United States;(4)Sanofi Research and Development- 1 avenue Pierre Brossolette- CHILLY-MAZARIN 91385- France, Sanofi Research and Development- 1 avenue Pierre Brossolette- CHILLY-MAZARIN 91385- France, Chilly-Mazarin, France;
P666: Effect of anastomotic configuration on Crohn's Disease recurrence after primary ileocolic resection. A comparative monocentric study of end-to-end versus side-to-side anastomosis.ECCO’23 CopenhagenYear: 2023
Authors: Bislenghi, G.(1);Vancoillie, P.J.(1)*;Fieuws, S.(2);Verstockt, B.(3);Sabino, J.(4);Wolthuis, A.(1);D'Hoore, A.(1);
(1)University Hospitals Leuven, Abdominal Surgery, Leuven, Belgium;(2)Catholic Univeristy Leuven and University of Hasselt, Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatolog, Leuven, Belgium;
P667: USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease– results from STEADY studyECCO’23 CopenhagenYear: 2023
Authors: Chin, A.(1)*;Jeffrey, A.(1);Teh, W.L.(1);Menon, S.(1);So, K.(1);Venugopal, K.(1);Picardo, S.(1);
(1)Royal Perth Hospital, Department of Gastroenterology, Perth, Australia;
P668: Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResourceECCO’23 CopenhagenYear: 2023
Authors: Kapizioni, C.(1)*;Desoki, R.(1,2);Balendran, K.(1);Lam, D.(1);Shawky, R.(3);Pele, L.(3);Parkes, M.(1);Raine, T.(1);
(1)Cambridge University Hospital, Gastroenterology Department, Cambridge, United Kingdom;(2)Alexandria University, Genetics Department, Alexandria, Egypt;(3)Cambridge University Hospital, IBD BioResource, Cambridge, United Kingdom;
P669: Improving Crohn's disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammationECCO’23 CopenhagenYear: 2023
Authors: Schulberg, J.D.(1,2)*;Hamilton, A.L.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Sutherland, T.(2,3);Ross, A.L.(1);Vogrin, S.(2);Kamm, M.A.(1,2);
(1)St. Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(2)The University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St. Vincent's Hospital, Department of Medical Imaging, Melbourne, Australia;
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?ECCO’23 CopenhagenYear: 2023
Authors: Sheldon, E.(1)*;Roman, S.(2);Randall, K.(2);Rachel, H.(3);Winsor, G.(4);Wakeman, R.(5);Lobo, A.(2);
(1)The University of Sheffield, School of Health and Related Research, Sheffield, British Virgin Islands;(2)Sheffield Teaching Hospitals NHS Foundation Trust, Gastroenterology, Sheffield, United Kingdom;(3)The University of Sheffield, School of Health and Related Research, Sheffield, United Kingdom;(4)Crohn's & Colitis UK, Research & Quality Improvement, Hatfield, United Kingdom;(5)Crohn's & Colitis UK, Services- Advocacy & Evidence, Hatfield, United Kingdom;on behalf of the AWARE-IBD Study Group
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extensionECCO’23 CopenhagenYear: 2023
Authors: Turner, D.(1)*;Rosh, J.R.(2);Cohen, S.A.(3);Griffiths, A.(4);Hyams, J.S.(5);Kierkuś, J.(6);Adedokun, O.J.(7);Strauss, R.(8);Kim, L.(9); Volger, S.(10);
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Goryeb Children's Hospital/Atlantic Health, Pediatric Gastroenterology, Morristown- NJ, United States;(3)GI Care for Kids, Pediatric Gastroenterology, Atlanta- GA, United States;(4)The Hospital for Sick Children- University of Toronto, Pediatric Gastroenterology, Toronto- ON, Canada;(5)Connecticut Children's Medical Center, Pediatric Gastroenterology, Hartford- CT, United States;(6)The Children's Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders- and Paediatrics, Warsaw, Poland;(7)Janssen Research and Development- LLC, Clinical Pharmacology, Spring House- PA, United States;(8)Janssen Research and Development- LLC, Immunology, Horsham- PA, United States;(9)Janssen Research and Development- LLC, Biostatistics, Spring House- PA, United States;(10)Janssen Research and Development- LLC, Immunology, Spring House- PA, United States;UniStar Investigators
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodiesECCO’23 CopenhagenYear: 2023
Authors: AnjieMD, S.(1)*;Hanžel, J.(2);Gecse, K.B.(1);D'Haens, G.R.(1);Brandse, J.F.(3);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)University Medical Center Ljubljana, Department of Gastroenterology and Hepatology, Ljubjana, Slovenia;(3)Rijnstate, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort studyECCO’23 CopenhagenYear: 2023
Authors: Jagt, J.(1,2)*;Galestin, S.(3);Benninga, M.(1);de Boer, N.(4);de Meij, T.(1);
(1)Amsterdam UMC- location University of Amsterdam, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Amsterdam UMC- Vrije Universiteit Amsterdam, Pediatric Gastroenterology- Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands;(3)Amsterdam UMC- location University of Amsterdam, Faculty of Medicine, Amsterdam, The Netherlands;(4)Amsterdam UMC- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology- Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands;
P674: Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohortECCO’23 CopenhagenYear: 2023
Authors: Verstockt., B.(1,2)*;Vieujean, S.(3);Truyens, M.(4,5);Julsgaard, M.(6);Pugliese, D.(7);Aslan, D.(1);Prokopic, M.(8);Lim, S.(9);Viganò, C.(10);Festa, S.(11);Ramos, L.(12);Garciá, M.J.(13);Plaza, R.(14);Noviello, D.(15);Savarino, E.(16);Drobne, D.(17);Imperatore, N.(18);Ribaldone, D.G.(19);Van Dongen, J.(20);Teich, N.(21);Wahed, M.(22);Barberio, B.(23);Goren, I.(24,25);
(1)University Hospitals Leuven, Dpt. Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Disease & Metabolism, Leuven, Belgium;(3)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(4)Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium;(5)Ghent University, Department of Internal Medicine and Paediatrics, Ghent, Belgium;(6)Aarhus University Hospital, Gastroenterology, Aarhus, Denmark;(7)Fondazione Policlinico “A Gemelli” IRCSS, Gastroenterology, Roma, Italy;(8)University Hospital Martin- Jessenius Faculty of Medicine- Comenius University, Department of Gastroenterology-, Bratislava, Slovakia;(9)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(10)San Gerardo Hospitol- University of Milan Bicocca, Gastroenterology, Monza, Italy;(11)San Filippo Neri Hospital, Gastroenterology, Roma, Italy;(12)Hospital Universitario de Canarias- Spain, Gastroenterology, Gran Canaria, Spain;(13)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology, Valdecilla, Spain;(14)Hospital Intana Leonor, Gastroenterology, Madrid, Spain;(15)University of Milan, Department of Pathophysiology and Transplantation-, Milano, Italy;(16)University of Paduo- Azienda Ospedaliera di Padova, Gastroenterology, Padova, Italy;(17)University Medical Centre, Gastroenterology, Ljubiljana, Slovenia;(18)Cardarelli Hospital of Naples, Gastroenterology, Naples, Italy;(19)Università degli Studi di Torino, Gastroenterology, Torino, Italy;(20)AZ Sint Maarten, Gastroenterology, Mechelen, Belgium;(21)Internistische Gemeinschaftspraxis für Verdauungs, Dpt. Gastroenterology, Liepzig, United Kingdom;(22)Chelsea and Westminster NHS Foundation Trust, Gastroenterology, London, United Kingdom;(23)University of Paduo- Azienda Ospedaliera di Padova, Gastroenterology, Padova, Italy;(24)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(25)Lerner Research Institute- Cleveland Clinic, Department of inflammation and immunity, Cleveland, United States;
P675: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseasesECCO’23 CopenhagenYear: 2023
Authors: Chaparro Sanchez, M.(1)*;Acosta, D.(1);Rodríguez, C.(2);Mesonero, F.(3);Vicuña, M.(2);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.(7);Vera, I.(8); Ruiz-Cerulla, A.(9);Sicilia, B.(10);Cabello Tapia, M.J.(11);Muñoz Villafranca, C.(12);Castro-Poceiro, J.(13);Martínez Cadilla, J.(14);Sierra-Ausín, M.(15);Vázquez Morón, J.M.(16);Montil Miguel, E.(17);Bermejo, F.(18);Royo, V.(19);Calafat, M.(20);González-Muñoza, C.(21);Leo Carnerero, E.(22);Manceñido Marcos, N.(23);Torrealba, L.(24); Alonso-Galán, H.(25);Benítez, J.M.(26);Ber Nieto, Y.(27);Diz-Lois Palomares, M.T.(28);García, M.J.(29);Muñoz, J.F.(30);Armesto González, E.M.(31);Calvet, X.(32); Hernández-Camba, A.(33);Madrigal Domínguez, R.E.(34);Menchén, L.(35);Pérez Calle, J.L.(36);Piqueras, M.(37);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM- and CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra HUN and Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain;(4)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Clinic of Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBERehd, Gastroenterology Unit, Barcelona, Spain;(6)Hospital Universitario Torrecárdenas, Gastroenterology Unit, Almería, Spain;(7)Hospital Clínico Universitario Lozano Blesa- IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(9)Hospital Universitario de Bellvitge, Gastroenterology Unit, L´Hospitalet de Llobregat, Spain;(10)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(11)Hospital Universitario Virgen de las Nieves, Gastroenterology Unit, Granada, Spain;(12)Hospital Universitario de Basurto, Gastroenterology Unit, Bilbao, Spain;(13)Hospital Sant Joan Despí-Moisès Broggi, Gastroenterology Unit, Barcelona, Spain;(14)Hospital Álvaro Cunqueiro. Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación en Patología Digestiva- IIS Galicia Sur. SERGAS-UVIGO, Gastroenterology Unit, Vigo, Spain;(15)Complejo Asistencia Universitario de León, Gastroenterology Unit, León, Spain;(16)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(17)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(18)Hospital Universitario de Fuenlabrada and IdiPAZ, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(20)Hospital Universitari Germans Trias i Pujol and CIBEREHD, Gastroenterology Unit, Badalona, Spain;(21)Hospital de la Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain;(22)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(23)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain;(24)Hospital Universitario Dr. Josep Trueta, Gastroenterology Unit, Girona, Spain;(25)Hospital Universitario Donostia and Instituto Biodonostia, Gastroenterology Unit, San Sebastián, Spain;(26)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(27)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(28)Complejo Hospitalario Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain;(29)Hospital Universitario de Valdecilla and Instituto de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology Unit, Santander, Spain;(30)Hospital Universitario de Salamanca, Gastroenterology Unit, Salamanca, Spain;(31)Hospital San Agustín, Gastroenterology Unit, Avilés, Spain;(32)Hospital Universitari Parc Taulí- Universitat Autònoma de Barcelona and CIBERehd, Gastroenterology Unit, Sabadell, Spain;(33)Complejo Hospitalario Universitario Nuestra Señora de Candelaria, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(34)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(35)Hospital General Universitario Gregorio Marañón, Gastroenterology Unit, Madrid, Spain;(36)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(37)Consorci Sanitari de Terrassa, Gastroenterology Unit, Barcelona, Spain;on behalf of To-ReWard study group
P676: Intestinal ultrasound accurately predicts therapy failure in Crohn's disease patients during a biologics-induced remissionECCO’23 CopenhagenYear: 2023
Authors: Albshesh, A.(1)*;Abend, A.(2); Margalit Yehuda, R.(1);Mahajna, H.(1);Ben-Horin, S.(1);Kopylov, U.(1);Carter, D.(1);
(1)Sheba Medical Center and Sackler School of Medicine- Tel-Aviv University, Department of Gastroenterology, Tel Hashomer, Israel;(2)Sheba Medical Center, Department of Internal Medicine F, Tel Hashomer, Israel;
P677: Combination of vedolizumab and exclusive enteral nutrition in patients with moderate to severe Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kang, J.(1,2,3);Wang, J.(1,2,3);Lu, Y.(4);Li, J.(1,2,3);Su, J.(1,2,3);Ying, A.(1,2,3);Ren, H.(1,2,3);Zhou, Q.(1,2,3);Wang, Y.(1,2,3);Ding, Y.(1,2,3);An, P.(1,2,3)*;
(1)Renmin Hospital of Wuhan University, Gastroenterology, Wuhan, China;(2)Renmin Hospital of Wuhan University, Hubei Provincial Clinical Research Center for Digestive Disease Minimally Invasive Incision, Wuhan, China;(3)Renmin Hospital of Wuhan University, Key Laboratory of Hubei Province for Digestive System Disease, Wuhan, China;(4)Jingzhou First People's Hospital, Gastroenterology, Jingzhou, China;
P678: Ustekinumab therapy improves the nutritional status in patients with Crohn's Disease. A prospective studyECCO’23 CopenhagenYear: 2023
Authors: BertaniMD, L.(1,2)*;D'Alessandro, C.(1);Fornili, M.(3);Coppini, F.(1);Zanzi, F.(1);Carmisciano, L.(3);Geri, F.(1);Baiano Svizzero, G.(4);Ceccarelli, L.(4);Mumolo, M.G.(4);Baglietto, L.(3);Bellini, M.(1);Costa, F.(4);De Bortoli, N.(1);
(1)University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy;(2)Tuscany North-West ASL - Pontedera Hospital, General Surgery and Gastroenterology, Pontedera, Italy;(3)University of Pisa, Clinical and Experimental Medicine, Pisa, Italy;(4)Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;
P680: A real-life experience of Crohn's Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Scarallo, L.(1)*;Fioretti, L.(1);Pochesci, S.(1);Pierattini, V.(2);Banci, E.(2);De Blasi, A.(1);Di Paola, M.(1);Lionetti, P.(1,3);
(1)Meyer Children Hospital, Gastroenterology and Nutrition Unit, Florence, Italy;(2)Meyer Children Hospital, Dietetics Unit, Florence, Italy;(3)University of Florence, Department of NEUROFARBA, Florence, Italy;
